Login
Companies $OPK
$1.62 +$0.00 (0.07%) After hours
OPKO HEALTH, INC. logo

OPKO HEALTH, INC.

opko.com

What Do They Do?

Provides clinical laboratory testing to physicians, hospitals and other health facilities, sells Rayaldee and NGENLA, and develops therapies for cancer and infectious diseases.

How Do They Make Money?

Insurers, government programs and client institutions pay for laboratory testing when results are reported; customers pay for products when they obtain them. OPKO also grants royalty-bearing licenses to development partners.

revenue
SegmentShareRevenue
Service
Usage-based

61%
FY2022: 75%
Product
Sold outright

26%
FY2022: 14%
Transfer of Intellectual Property and Other
Licensed

13%
FY2022: 11%

Who Are Their Customers?

BioReference markets tests directly to healthcare providers and facilities, including physician offices, hospitals, clinics and correctional facilities. Insurers and government programs reimburse tests; client institutions and patients are also billed.

Do Revenues Turn Into Profits?

No. It lost $225.7M in FY2025.

Operating income, FY2025
−19% of revenue
▲ +23% (Loss) vs FY2024 (−$152.1M, −21%)
Net income, FY2025
−37% of revenue
▼ −324% (Loss) vs FY2024 (−$53.2M, −7%)
Free cash flow, FY2025
−31% of revenue
▲ +8% (Loss) vs FY2024 (−$208.5M, −29%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +16%
vs $56.4M in Q3 FY2025
Net income
▼ Turned to a loss
vs $21.6M in Q3 FY2025
  • Jul 27, 2026 Expanded Nicoya agreement for Rayaldee in Greater China The amendment gives OPKO a 15% equity stake in Nicoya in exchange for revised royalty and transfer-price terms, and broadens the agreement's field of use.

Shrinking. Revenue fell 66% in 4 years, from $1.8B in FY2021 to $606.9M in FY2025, about 24% a year.

A narrower diagnostics business The older report describes a broad, nationwide BioReference laboratory offering many types of testing; the latest report centers the remaining business on clinical and women's health testing in New York and New Jersey and a national urology franchise after asset sales.

Revenue over time
Service Product Transfer of Intellectual Property and Other
$2B$1B$0

Who Do They Compete With?

Competes with Ascendis Pharma and Novo Nordisk

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support